TY - JOUR
T1 - The effects of sesame, canola, and sesame–canola oils on cardiometabolic markers in patients with type 2 diabetes
T2 - a triple-blind three-way randomized crossover clinical trial
AU - Amiri, Mojgan
AU - Raeisi-Dehkordi, Hamidreza
AU - Moghtaderi, Fatemeh
AU - Zimorovat, Alireza
AU - Mohyadini, Matin
AU - Salehi-Abargouei, Amin
N1 - Funding Information:
The current study was funded by Shahid Sadoughi University of Medical Sciences ( http://www.ssu.ac.ir ) and Neshatavar food industry (Datis Corporation; http://www.neshatavar.com/?l=EN ). Datis Corporation also provided all the treatment oils consumed during the study including canola, sesame, sesame–canola and sunflower oils. Datis Corporation had no role in design and conduct of this manuscript; collection, management, analysis, and interpretation of the data; and preparation of this manuscript.
Funding Information:
We appreciate the participants for their voluntary involvement in the project. In addition, we are thankful from Shahid Sadoughi University of Medical Sciences and Neshatavar food industry company (Datis Corporation) for their joint funding of this study. Additionally, scientific support and close cooperation of research council of Nutrition and Food Security Research Center and diabetes research center of Shahid Sadoughi University of Medical Sciences, Yazd, Iran, are greatly appreciated.
Funding Information:
The study was jointly funded by Shahid Sadoughi University of Medical sciences and Datis Corporation. The investigators declared that they did not have a direct financial relationship with Datis Corporation and Shahid Sadoughi University of Medical Sciences received the funds and delivered them to the investigators. Datis Corporation did not take any part in the conception, design, the execution of the study protocol, and the reporting of the study results. The corporation did not have any other relationship with the investigators. The authors declare that they have no other potential personal or financial conflicts of interest. The principal investigator (ASA) declares that he has full access to the data and samples provided by this project.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
PY - 2022/10
Y1 - 2022/10
N2 - Aims: To compare the effects of replacing regular dietary oils intake with sesame (SO), canola (CO), and sesame–canola (SCO) oils (a novel blend), on cardiometabolic markers in adults with type 2 diabetes mellitus (T2DM), in a triple-blind, three-way, randomized, crossover clinical trial. Methods: Participants were assigned to receive SO, CO, and SCO in three 9-week phases (4 weeks apart). Cardiometabolic makers (serum lipids, Apolipoprotein, cardiovascular risk scores, kidney markers, and blood pressure) were considered at the beginning and the end of intervention phases. Results: Ninety-two, ninety-five, and ninety-five participants completed the SO, SCO, and CO periods, respectively. After CO consumption, serum Apo A-1 concentrations were significantly higher compared with the SCO period in the whole population (p < 0.05). A considerable reduction in visceral adiposity index values was seen in the CO compared with the SO period in males (p < 0.05). Serum high-density lipoprotein concentration was also significantly higher after the SO intake compared with SCO in females (p < 0.05). The between-period analysis showed a substantial reduction in diastolic blood pressure in the SCO period compared with the CO and SO periods and lower systolic blood pressure after SCO versus CO intake in males (p < 0.05). Conclusions: Canola oil might protect CVD through improving Apo A-1 levels in patients with T2DM (particularly in females) and visceral adiposity index in male patients. However, the blend oil might beneficially affect blood pressure in men. Future sex-specific studies might warrant the current findings. Registry of clinical trials: This trial was registered in the Iranian Registry of Clinical Trials (IRCT, registration ID: IRCT2016091312571N6).
AB - Aims: To compare the effects of replacing regular dietary oils intake with sesame (SO), canola (CO), and sesame–canola (SCO) oils (a novel blend), on cardiometabolic markers in adults with type 2 diabetes mellitus (T2DM), in a triple-blind, three-way, randomized, crossover clinical trial. Methods: Participants were assigned to receive SO, CO, and SCO in three 9-week phases (4 weeks apart). Cardiometabolic makers (serum lipids, Apolipoprotein, cardiovascular risk scores, kidney markers, and blood pressure) were considered at the beginning and the end of intervention phases. Results: Ninety-two, ninety-five, and ninety-five participants completed the SO, SCO, and CO periods, respectively. After CO consumption, serum Apo A-1 concentrations were significantly higher compared with the SCO period in the whole population (p < 0.05). A considerable reduction in visceral adiposity index values was seen in the CO compared with the SO period in males (p < 0.05). Serum high-density lipoprotein concentration was also significantly higher after the SO intake compared with SCO in females (p < 0.05). The between-period analysis showed a substantial reduction in diastolic blood pressure in the SCO period compared with the CO and SO periods and lower systolic blood pressure after SCO versus CO intake in males (p < 0.05). Conclusions: Canola oil might protect CVD through improving Apo A-1 levels in patients with T2DM (particularly in females) and visceral adiposity index in male patients. However, the blend oil might beneficially affect blood pressure in men. Future sex-specific studies might warrant the current findings. Registry of clinical trials: This trial was registered in the Iranian Registry of Clinical Trials (IRCT, registration ID: IRCT2016091312571N6).
KW - Apolipoprotein
KW - Canola oil
KW - Cardiovascular risk factors
KW - Dietary oils
KW - Dyslipidemia
KW - Hypertension
KW - Lipids
KW - Lipoproteins
KW - Rapeseed oil
KW - Sesame oil
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85130305414&partnerID=8YFLogxK
U2 - 10.1007/s00394-022-02898-9
DO - 10.1007/s00394-022-02898-9
M3 - Article
C2 - 35596008
AN - SCOPUS:85130305414
SN - 1436-6207
VL - 61
SP - 3499
EP - 3516
JO - European Journal of Nutrition
JF - European Journal of Nutrition
IS - 7
ER -